71 related articles for article (PubMed ID: 18840484)
1. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
2. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
3. Comparative Evaluation of Cellular Uptake of Free and Liposomal Doxorubicin Following Short Term Exposure.
Zaleskis G; Garberyte S; Pavliukeviciene B; Krasko JA; Skapas M; Talaikis M; Darinskas A; Zibutyte L; Pasukoniene V
Anticancer Res; 2021 May; 41(5):2363-2370. PubMed ID: 33952461
[TBL] [Abstract][Full Text] [Related]
4. CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
Erin N; Dilmaç S; Curry A; Duymuş Ö; Tanriover G; Prodeus A; Gariepy J; Gorczynski RM
Cancer Immunol Immunother; 2020 Jan; 69(1):103-114. PubMed ID: 31811336
[TBL] [Abstract][Full Text] [Related]
5. Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma.
Viale M; Bertone V; Maric I; Cilli M; Emionite L; Bocchini V; Ponzoni M; Fontana V; De Luca F; Rocco M
Pharmacol Res; 2021 Jan; 163():105294. PubMed ID: 33217536
[TBL] [Abstract][Full Text] [Related]
6. Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice.
Khan MA; Aljarbou AN; Aldebasi YH; Alorainy MS; Khan A
Int J Nanomedicine; 2015; 10():6331-8. PubMed ID: 26504383
[TBL] [Abstract][Full Text] [Related]
7. Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin.
Yu YF; Wu EC; Lin SQ; Chu YX; Yang Y; Pan F; Ding TH; Qian J; Jiang K; Zhan CY
Acta Pharmacol Sin; 2024 Mar; 45(3):646-659. PubMed ID: 37845342
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier.
Yokoi K; Chan D; Kojic M; Milosevic M; Engler D; Matsunami R; Tanei T; Saito Y; Ferrari M; Ziemys A
J Control Release; 2015 Nov; 217():293-9. PubMed ID: 26409121
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of cold atmospheric pressure plasma and free or liposomal doxorubicin on melanoma cells.
Pefani-Antimisiari K; Athanasopoulos DK; Marazioti A; Sklias K; Rodi M; de Lastic AL; Mouzaki A; Svarnas P; Antimisiaris SG
Sci Rep; 2021 Jul; 11(1):14788. PubMed ID: 34285268
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin.
Yokomichi N; Nagasawa T; Coler-Reilly A; Suzuki H; Kubota Y; Yoshioka R; Tozawa A; Suzuki N; Yamaguchi Y
Hum Cell; 2013 Mar; 26(1):8-18. PubMed ID: 23386177
[TBL] [Abstract][Full Text] [Related]
11. Controlling the Biological Fate of Liposomal Spherical Nucleic Acids Using Tunable Polyethylene Glycol Shells.
Zhang W; Callmann CE; Mirkin CA
ACS Appl Mater Interfaces; 2021 Oct; 13(39):46325-46333. PubMed ID: 34547202
[TBL] [Abstract][Full Text] [Related]
12. DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement.
Mai J; Li X; Zhang G; Huang Y; Xu R; Shen Q; Lokesh GL; Thiviyanathan V; Chen L; Liu H; Zu Y; Ma X; Volk DE; Gorenstein DG; Ferrari M; Shen H
Mol Pharm; 2018 May; 15(5):1814-1825. PubMed ID: 29537266
[TBL] [Abstract][Full Text] [Related]
13.
Karimi M; Sadeghi E; Zahedifar M; Nejati M; Mirzaei H; Hamblin MR
Front Bioeng Biotechnol; 2023; 11():1286955. PubMed ID: 38076426
[TBL] [Abstract][Full Text] [Related]
14. Efficient Drug Loading Method for Poorly Water-Soluble Drug into Bicelles through Passive Diffusion.
Arai Y; Iwao Y; Muguruma Y; Yamamoto K; Ikeda Y
Mol Pharm; 2023 Nov; 20(11):5701-5713. PubMed ID: 37823379
[TBL] [Abstract][Full Text] [Related]
15. BioMOF-Based Anti-Cancer Drug Delivery Systems.
Elmehrath S; Nguyen HL; Karam SM; Amin A; Greish YE
Nanomaterials (Basel); 2023 Mar; 13(5):. PubMed ID: 36903831
[TBL] [Abstract][Full Text] [Related]
16. One-Step Pharmaceutical Preparation of PEG-Modified Exosomes Encapsulating Anti-Cancer Drugs by a High-Pressure Homogenization Technique.
Fukuta T; Ikeda-Imafuku M; Kodama S; Kuse J; Matsui K; Iwao Y
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678605
[TBL] [Abstract][Full Text] [Related]
17. Silk Fibroin-Coated Liposomes as Biomimetic Nanocarrier for Long-Term Release Delivery System in Cancer Therapy.
Suyamud C; Phetdee C; Jaimalai T; Prangkio P
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443524
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy.
Rommasi F; Esfandiari N
Nanoscale Res Lett; 2021 May; 16(1):95. PubMed ID: 34032937
[TBL] [Abstract][Full Text] [Related]
19. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
[TBL] [Abstract][Full Text] [Related]
20. Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy.
Naik H; Sonju JJ; Singh S; Chatzistamou I; Shrestha L; Gauthier T; Jois S
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33800723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
